The production development at Abzena proceeds successfully

At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have been done and SOL-116 is on its way to Umeå. An enthusiastic team is waiting impatiently to continue with further studies.


Lipum strengthens Board with experienced docent

At the end of last year, we were able to announce that the cell line had been completed. Recently, another good news was brought, a significant reinforcement to the company's board. BioStock took the opportunity to talk to Lipum's new addition to the boardroom, Dr. Kristian Sandberg, about his thoughts about Lipum and what he [...]


SwedenBIO opens a Q&A function

SwedenBIO has opened up a Q&A function on their website. Here, questions can be asked about the Swedish life science industry's role in meeting current challenges. Click here to get to Q&A »


Dr Kristian Sandberg new board member of Lipum

Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. He has experiences from the development of both protein and conventional small molecule based drugs from concept [...]


Dr Kristian Sandberg suggested as new board member

Press release Februari 18, 2020 The board of directors of Lipum AB has suggested Dr Kristian Sandberg to be elected as new member of the board at an extraordinary general meeting held in Umeå on March 3, 2020. Lipum has identified bile salt-stimulated lipase (BSSL) as a novel target for treatment of chronic inflammatory diseases. [...]


Lipum kallar till extra bolagsstämma

Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg väljs som ordinarie styrelseledamot i Lipum AB. Ladda ned kallelse här »


A milestone has been reached

After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical trials as planned during 2021. [...]


Professor Anders Fasth joins the scientific advisory board

Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of [...]

Till toppen